SG11201900810WA - Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use - Google Patents

Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use

Info

Publication number
SG11201900810WA
SG11201900810WA SG11201900810WA SG11201900810WA SG11201900810WA SG 11201900810W A SG11201900810W A SG 11201900810WA SG 11201900810W A SG11201900810W A SG 11201900810WA SG 11201900810W A SG11201900810W A SG 11201900810WA SG 11201900810W A SG11201900810W A SG 11201900810WA
Authority
SG
Singapore
Prior art keywords
composition
fibroblasts
treatment
injection
heart diseases
Prior art date
Application number
SG11201900810WA
Other languages
English (en)
Inventor
Takahiro Iwamiya
Original Assignee
Metcela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metcela Inc filed Critical Metcela Inc
Publication of SG11201900810WA publication Critical patent/SG11201900810WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33Fibroblasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201900810WA 2017-02-24 2018-02-23 Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use SG11201900810WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017033624 2017-02-24
PCT/JP2018/006795 WO2018155651A1 (ja) 2017-02-24 2018-02-23 線維芽細胞を含む心臓疾患を治療するための注射用組成物、及び治療用線維芽細胞の製造方法

Publications (1)

Publication Number Publication Date
SG11201900810WA true SG11201900810WA (en) 2019-02-27

Family

ID=63253929

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900810WA SG11201900810WA (en) 2017-02-24 2018-02-23 Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use

Country Status (12)

Country Link
US (2) US11096969B2 (enExample)
EP (1) EP3476395B1 (enExample)
JP (2) JP6618066B2 (enExample)
KR (1) KR102407387B1 (enExample)
CN (1) CN109890398B (enExample)
AU (1) AU2018223739B2 (enExample)
CA (1) CA3032654A1 (enExample)
DK (1) DK3476395T3 (enExample)
ES (1) ES2885080T3 (enExample)
IL (1) IL267958B2 (enExample)
SG (1) SG11201900810WA (enExample)
WO (1) WO2018155651A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3110831A1 (en) 2018-08-29 2020-03-05 Metcela Inc. Method for producing fibroblast, and g-csf-positive fibroblast mass
CN109589337B (zh) 2018-12-29 2022-04-26 南京艾尔普再生医学科技有限公司 心肌细胞制剂及其制备方法和应用
IL296125A (en) 2020-03-04 2022-11-01 Metcela Inc Fibroblasts have an increased ability to produce erythropoietin
AU2022231584A1 (en) * 2021-03-04 2023-09-07 Lymphogenix Limited Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease
EP4249585A1 (en) * 2022-03-25 2023-09-27 Technische Universität München - TUM Heart tissue models, method of producing heart tissue models and uses of heart tissue models

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
CA2487254A1 (en) * 2002-05-08 2003-11-20 The Regents Of The University Of California System and method for treating cardiac arrhythmias with fibroblast cells
AU2003239418B2 (en) * 2002-05-08 2008-01-31 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US20040161412A1 (en) * 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
CN101415458A (zh) * 2003-11-10 2009-04-22 辛弗尼医药有限公司 控制心房纤维性颤动患者心室律的方法
US8513011B2 (en) * 2004-08-26 2013-08-20 Biotech Research Ventures Pte Limited Methods and compositions for culturing cardiomyocyte-like cells
ES2325715B1 (es) * 2007-08-03 2010-06-17 Genetrix, S.L. Poblacion de celulas madre adultas derivadas de tejido adiposo cardiaco y su uso en regeneracion cardiaca.
JP5378743B2 (ja) 2008-09-30 2013-12-25 テルモ株式会社 医療用細胞シートの製造方法
WO2013028968A1 (en) * 2011-08-25 2013-02-28 Wisconsin Alumni Research Foundation 3-dimensional cardiac fibroblast derived extracellular matrix
EP2826855B1 (en) 2012-03-15 2018-08-29 iHeart Japan Corporation Myocardial sheet
US20140072611A1 (en) * 2012-09-07 2014-03-13 Fibrocell Technologies, Inc. Methods and Compositions for Treating Post-Cardial Infarction Damage
GB201309057D0 (en) * 2013-05-20 2013-07-03 Cell Therapy Ltd Method
KR20150009655A (ko) * 2013-07-16 2015-01-27 학교법인 동아학숙 Gcp-2 유전자를 과발현하는 지방 간엽줄기세포를 포함하는 허혈성 질환 치료용 조성물
CA2954743C (en) * 2014-07-11 2022-03-15 Metcela Inc. Cardiac cell culture material

Also Published As

Publication number Publication date
EP3476395A4 (en) 2020-02-26
CN109890398B (zh) 2024-01-16
CN109890398A (zh) 2019-06-14
IL267958A (en) 2019-09-26
AU2018223739A1 (en) 2019-02-14
US20210346436A1 (en) 2021-11-11
EP3476395A1 (en) 2019-05-01
CA3032654A1 (en) 2018-08-30
IL267958B2 (en) 2023-08-01
JP7072135B2 (ja) 2022-05-20
IL267958B1 (en) 2023-04-01
EP3476395B1 (en) 2021-07-21
WO2018155651A1 (ja) 2018-08-30
DK3476395T3 (da) 2021-08-16
JP2019218408A (ja) 2019-12-26
JP6618066B2 (ja) 2019-12-11
US20190224250A1 (en) 2019-07-25
KR20190117468A (ko) 2019-10-16
US11096969B2 (en) 2021-08-24
AU2018223739B2 (en) 2023-06-22
KR102407387B1 (ko) 2022-06-10
JPWO2018155651A1 (ja) 2019-11-07
ES2885080T3 (es) 2021-12-13

Similar Documents

Publication Publication Date Title
SG11201900810WA (en) Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use
PH12020500555A1 (en) Esketamine for the treatment of depression
MX392869B (es) Kit para el tratamiento o alivio de dolor en el sitio de incision despues de un procedimiento quirurgico
MX2021007592A (es) Compuestos macrociclicos y su uso en el tratamiento de enfermedades.
MX395523B (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
CL2015001700A1 (es) Tratamiento de trastornos del ritmo circadiano
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
TN2016000147A1 (en) Compositions for body reconstruction and body-shaping.
AR103118A1 (es) Tratamientos médicos basados en anamorelina
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2025004900A (es) Tratamiento de verrugas
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EP4389218A3 (en) Composition for treating joint disease and kit containing same
MX2022001450A (es) Metodo de tratamiento del cancer.
MX2021009384A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
EA202193276A1 (ru) Способы лечения холангиокарциномы
EA201591693A1 (ru) Новые соединения, модулирующие контроль над дыханием, и способы их применения
WO2019179823A8 (en) Lactobacillus fermentum for treating fructose-related diseases
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
PH12022551512A1 (en) Synthetic processes and intermediates
PH12021550656A1 (en) Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
CN204050302U (zh) 一种携带式腕踝针针刺点压迫治疗装置